ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to âtarget a better now.â The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.
Source
